Keeping pace with a growing need for accelerated innovation is leaving the traditional experiment model of “design, test, repeat” in the dust. Unnecessary physical experimentation takes too long and costs too much. In response, today’s leaders in the CPG industry are embracing the benefits offered by in silico modeling and simulation. These organizations are exploring the varied physical and chemical interactions that power their products and optimizing them. They are making game-changing innovations that have allowed them to design new, groundbreaking products. These benefits offered by modeling and simulation go beyond improved agility or financial gains—they are transformative.

While we like to imagine research facilities as being centers of cutting edge technology and streamlined efficiency, sometimes the reality couldn’t be further from the truth. In many laboratories, researchers still rely on paper notebooks to hold all information pertaining to current experiments: protocols, calculations, assay parameters, and any deviations. […]

This year at Science in the Age of Experience, we at BIOVIA are very fortunate to have a very strong lineup of customer presentations to highlight the deeper functionalities of the BIOVIA solution portfolio. We believe that these presentations by customers, for customers, can provide some real-world insight into unique use cases which could be the source of transformative value at your organization.

Professor Martin Karplus, the 2013 Nobel Laureate in Chemistry and the Theodore William Richards Professor of Chemistry, emeritus at Harvard University will be providing a keynote address this year at Science in the Age of Experience. His research team focuses on understanding the electronic structure, geometry, and dynamics of molecules of chemical and biological interest. After three decades of work their research has produced the groundbreaking molecular modeling engine CHARMM.

Politicians have never been shy about picking targets upon which to build platforms or make their pet issues. Unfortunately, due to rising healthcare costs and the public perception of drug prices, the pharmaceutical industry has become an easy target. The pressure upon lawmakers to do something has become enough that even presidential hopefuls who have traditionally supported the pharmaceutical industry have taken to attacking manufacturers of biologic drugs and other medical therapies. It is perhaps not the most surprising turn of events, but the added attention puts companies in an awkward position. To further complicate matters, legislators aren’t waiting until after the upcoming Presidential election to take action. The future of the Trans-Pacific Partnership remains uncertain, but Congressional committees are ramping up industry oversight. Both the House and Senate has dedicated resources toward investigating pricing practices and taking action to curtail rising costs. The increased scrutiny has cast a shadow over recent successes of the pharmaceutical industry—namely that we’ve seen the accelerated development of major new therapies. In 2014, the FDA approved 41 new drugs, 10 of which were biologic drugs.

The following is a guest post by Dassault Systèmes’ Adrian Stevens, Senior Manager of Modeling & Simulations and Tim Moran, Director of Product Marketing, Biologics. To view the exclusive webinar “A closer look at Dassault Systemès Designed to Cure Industry Solutions Experience,” click here. When you’re inside a maze, it’s difficult to […]

Current regulatory guidelines for the pharmaceutical industry are growing more stringent than ever, with strict adherence to quality standards taking top priority. Furthermore, the increased scrutiny shows no signs of lessening anytime soon. In recent years, the FDA has trended toward issuing more warning letters to life sciences facilities and […]

Page 27 of 99« First...1020...2526272829...405060...Last »